Cervical Cancer Screening Guidelines

Introduction to Cervical Cancer Screening

• Cervical cancer screening is essential for early detection and prevention of cervical cancer, with various organizations providing guidelines for screening, including the American Cancer Society, the USPSTF, and the American College of Obstetricians and Gynecologists 1, 2, 3, 4, 5, 6

Discontinuation of Screening

• Women can discontinue cervical cancer screening after age 65 if they have had at least 3 consecutive negative cytology tests or at least 2 consecutive negative HPV/Pap cotests within the past 10 years, with the most recent test occurring within the last 5 years, as recommended by the American Cancer Society, USPSTF, and American College of Obstetricians and Gynecologists 1, 6
• Women with no history of high-grade precancerous lesions (CIN2+) within the past 20-25 years, no history of cervical cancer, and not immunocompromised, who have had at least 3 consecutive negative Pap tests OR at least 2 consecutive negative HPV/Pap cotests within the past 10 years, and have a most recent screening test performed within the last 5 years, are eligible for screening cessation, according to the National Comprehensive Cancer Network guidelines 7
• Once screening is discontinued, it should not resume for any reason, including if a woman has a new sexual partner 1

Screening Frequency and Risks

• Annual cervical cancer screening is not recommended for any age group 1, 7
• The risk of developing cervical cancer after age 65 with normal prior screening is extremely low, and the harms of screening outweigh benefits in this population 6
• Women aged 21-29 should undergo cervical cytology alone every 3 years, and women aged 30-65 should undergo HPV and cytology cotesting every 5 years (preferred) OR cervical cytology alone every 3 years, as recommended by the National Comprehensive Cancer Network guidelines 7
• The preferred approach for women aged 30-65 years is HPV testing alone every 5 years, or HPV and cytology cotesting every 5 years, or cytology alone every 3 years, as recommended by the American Cancer Society and the USPSTF 8, 9, 10

Special Considerations

• Women with a history of cervical intraepithelial neoplasia grade 2 (CIN2) or more severe diagnosis within the past 20-25 years should continue screening beyond age 65, as recommended by the American Cancer Society 3
• Women with in utero exposure to diethylstilbestrol (DES) or immunocompromised status should continue screening beyond age 65, according to the American Cancer Society 3
• Women older than 65 years should continue to be screened if they have ASC-US (atypical squamous cells of undetermined significance), even if they are HPV-negative, as recommended by the National Comprehensive Cancer Network guidelines 7

Harms of Overscreening

• Continuing screening in women over 65 with adequate prior screening could lead to false positive results, unnecessary procedures, psychological distress, and physical discomfort, with no improvement in mortality or morbidity outcomes, as reported in the Annals of Internal Medicine 11
• Overscreening can lead to unnecessary procedures, patient anxiety, increased healthcare costs, and potential harms from false positive results, as stated by the American Cancer Society and other organizations 1, 12, 13, 14

Guidelines by Organization

1, 2, 3, 4, 5, 6

Patient Education and Awareness

• Many women remain unaware of current screening recommendations and options, highlighting the need for education and awareness about cervical cancer screening guidelines 15
• Healthcare providers should inform patients about the risks and benefits of screening, as well as the recommended screening schedule, to ensure informed decision-making, as stated by the American Cancer Society and other organizations 1, 2, 3, 6